Applications

Organoid Solutions

I. Core Characteristics of Organoids

Organoids are three-dimensional cell culture systems derived from pluripotent stem cells or adult stem cells, capable of highly simulating the physiological structure and functional characteristics of human organs. Their core advantages include:

1. Preservation of the donor tissue's genetic  background and phenotypic traits

2. Support for long-term in vitro culture and genetic editing

3. Applicability to high-throughput drug screening and dynamic monitoring

II. Core Applications in Drug Development

(A) Precision Drug Screening

1. Gastric Cancer Chemotherapy Evaluation: Sun Yat-sen University established 73 organoid models (78% success rate), achieving 91.7% accuracy in predicting chemotherapy drug sensitivity, and identified key biomarkers such as the STAT3 pathway.

2. Rare Disease Treatment: Cardiac organoids validated the gene repair efficacy of ASO drugs for Duchenne muscular dystrophy, reducing the evaluation cycle to 2 months.

3. Dynamic Monitoring Technology: Kunming Medical University developed a graphene field-effect platform for non-invasive monitoring of albumin secretion in liver organoids.

(B) Toxicity Evaluation System

1. Hepatotoxicity Assessment: Tsinghua Changgung Hospital led the development of the first organoid toxicity evaluation standard, significantly improving prediction accuracy.

2. Nephropathy Model: iPSC-derived polycystic kidney organoids demonstrated minoxidil's ability to suppress cyst formation and revealed new autophagy regulatory mechanisms.

3. COVID-19 Research: Lung organoid models uncovered viral entry pathway variations and successfully evaluated antifibrotic drug efficacy.

(C) Personalized Medicine

Colorectal cancer organoid experiments revealed significant individual differences in the efficacy of 5-fluorouracil and regorafenib. Xenograft models validated the tumor-specific inhibitory effects of drugs like trametinib.

III. Technological Breakthroughs

(A) Mechanism Analysis Technologies

1. Multi-omics Analysis: Single-cell sequencing identified five drug-response patterns and elucidated dynamic changes in the Wnt/MAPK pathway.

2. Disease Modeling: iPSC-derived brain organoids successfully simulated ALS neuronal degeneration, integrating AI to optimize target screening.

(B) Alternatives to Animal Testing

1. Policy Support: The FDA’s 2025 policy includes organoids in GLP-compliant alternatives, potentially reducing animal use by 90% in monoclonal antibody development.

2. Standardization: China has released four group standards, covering key technical specifications such as the construction of liver and gallbladder tumor models.

IV. Cutting-Edge Directions

1. Multi-organ Chips: Liver-intestine-heart interaction models for systemic metabolism simulation.

2. AI-Driven Analysis: Accelerating drug repositioning through AI-powered multi-omics data interpretation.

EnkiLife offers a comprehensive range of cytokines and biomarker antibodies for organoid research, including proteins and antibodies across multiple expression systems.

References

1. Personalized drug screening using patient-derived organoids and its clinical relevance in gastric cancer. DOI: 10.1016/j.xcrm.2024.101627